Quantcast

Latest Apolipoprotein A1 Stories

2014-09-02 08:30:49

Presented in 'State of the Art and Featured Research Session' at the 2014 European Society of Cardiology Congress TSX Exchange Symbol: RVX BARCELONA, Spain and CALGARY, AB, Sept. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) announced today that Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix delivered an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Spain. In his presentation, entitled: 'Effects of...

2014-07-23 08:32:18

In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism. TSX Exchange Symbol: RVX CALGARY, July 23, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) announced today findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in patients with diabetes mellitus (DM) enrolled in both the ASSURE and SUSTAIN trials. In ASSURE, MACE was a pre-specified...

2014-05-21 08:29:20

"Most Advanced Epigenetic Drug in Clinical Development" TSX Exchange Symbol: RVX CALGARY, May 21, 2014 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) today announced that its lead compound in clinical development, RVX-208, was prominently featured in the prestigious life science publication SciBX. SciBX: Science-Business eXchange is a weekly publication that focuses on scientific acumen of Nature Publishing Group with the business intelligence of BioCentury...

2014-03-31 12:29:54

"RVX-208 decreases Major Adverse Cardiac Events (MACE) in patients with systemic inflammation" TSX Exchange Symbol: RVX CALGARY, March 31, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that ASSURE data will be presented at the ACC conference in Washington DC. The poster titled "Effects of an Apolipoprotein A-1 Inducer on Progression of Coronary Atherosclerosis and Cardiovascular Events in Patients with Elevated Inflammatory Markers" will be presented by...

2014-03-17 16:28:30

"European Patent Office Grants RVX-208 Patent Until 2027" "Resverlogix Receives $2.5 Million for Non-Core ApoA-I Assets" TSX Exchange Symbol: RVX CALGARY, March 17, 2014 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) is pleased to announce today that it has received confirmation that its European patent application covering RVX-208 has been granted. European Patent no. 2118074 is titled "Compounds for the prevention and treatment of...

2014-01-27 10:30:58

Dysfunctional version of normally protective protein that makes HDL found to promote inflammation and coronary artery disease Cleveland Clinic researchers have discovered the process by which high-density lipoprotein (HDL) – the so-called "good cholesterol" – becomes dysfunctional, loses its cardio-protective properties, and instead promotes inflammation and atherosclerosis, or the clogging and hardening of the arteries. Their research was published online today in the journal Nature...

2014-01-15 16:23:31

"RVX-208 treated patients have significant lower MACE events in high risk CVD patients" TSX Exchange Symbol: RVX CALGARY, Jan. 15, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced new information arising from its ongoing analysis of data from both the SUSTAIN and ASSURE trials in atherosclerotic patients with high risk for recurrent events. This analysis, performed by an independent firm focuses on the potential benefit of RVX-208, a first in class...

2014-01-02 16:22:10

TSX Exchange Symbol: RVX CALGARY, Jan. 2, 2014 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that a publication titled "RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist" was published on December 31(st) 2013 in the international, peer-reviewed, open-access online publication PLOS ONE Journal. The publication was authored by Resverlogix staff in combination with collaborators from Xtal Biostructures Inc. in Maryland USA. This publication...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.